Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + nab-paclitaxel with or without radiotherapy for borderline resectable pancreatic cancer
jRCTs051200130Phase 2Recruiting
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC) (2 arms). Primary endpoint: 3-year survival rate. Started Feb 2021; status: recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCTs051200130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200130.